Mind the gap: can we explain declining male reproductive health with known antiandrogens?

Andreas Kortenkamp, Martin Scholze and Sibylle Ermler

Institute for the Environment, Brunel University, Kingston Lane, Uxbridge UB8 3PH, UK
Correspondence should be addressed to A Kortenkamp; Email: andreas.kortenkamp@brunel.ac.uk

Abstract

Several countries have experienced rises in cryptorchidisms, hypospadias and testicular germ cell cancer. The reasons for these trends are largely unknown, but Skakkebaek has proposed that these disorders form a testicular dysgenesis syndrome and can be traced to androgen insufficiency in foetal life. This suggests that antiandrogenic chemicals might contribute to risks, but few chemicals have been linked to these diseases in epidemiological studies. In animal studies with \( p,p'-\text{dichlorodiphenyldichloroethylene} \), effects typical of disruptions of male sexual differentiation became apparent when the foetal levels of this androgen receptor (AR) antagonist approached values associated with responses in \textit{in vitro} assays. This prompted us to analyse whether the 22 chemicals with AR antagonistic properties would produce mixture effects in an \textit{in vitro} AR antagonism assay when combined at concentrations found in human serum. Other antiandrogenic modalities could not be considered. Two scenarios were investigated, one representative of average serum levels reported in European countries, the other in line with levels towards the high exposures. In both situations, the \textit{in vitro} potency of the 22 selected AR antagonists was too low to produce combined AR antagonistic effects at the concentrations found in human serum, although the high exposure scenario came quite close to measurable effects. Nevertheless, our analysis exposes an explanation gap which can only be bridged by conjuring up as yet undiscovered high potency AR antagonists or, alternatively, high exposures to unknown agents of average potency.

\textit{Reproduction} (2014) 147 515–527

Introduction

In recent years, several countries have experienced increases in the incidence of cryptorchidisms (reviewed by Main \textit{et al.} (2010)) and hypospadias (Pierik \textit{et al.} 2002, Boisen \textit{et al.} 2005, Nelson \textit{et al.} 2005, Nassar \textit{et al.} 2007), the most frequent congenital malformations in young boys. The incidence of testicular germ cell cancers has risen steadily in Caucasian white men (Chia \textit{et al.} 2010) and is now the most commonly diagnosed malignant neoplasm among men of 15–34 years of age.

There are clear regional differences, but factors that fully explain these trends and differences have remained elusive. Although alcohol consumption, low birth weight, premature birth and diets lacking in protein are recognised risk factors for cryptorchidism and hypospadias, these alone cannot account for the current disease trends. Skakkebaek \textit{et al.} (2001) have proposed that cryptorchidisms and hypospadias are part of a syndrome that also comprises poor semen quality and testicular germ cell cancers, termed testicular dysgenesis syndrome (TDS). Changes in anogenital distance (AGD) are now also considered part of the TDS, since AGD is a biomarker of androgen action in foetal life that stays into adult life (Swan \textit{et al.} 2005). The TDS hypothesis suggests that its component disorders arise from insufficient androgen action in foetal life and proposes that exposures to antiandrogenic chemicals are an aetiological factor. In this context, antiandrogenicity is commonly understood to include several modes of action, such as androgen receptor (AR) antagonism and suppression of foetal androgen synthesis, all resulting in androgen insufficiency.
Epidemiological studies demonstrating associations between antiandrogenic chemicals and TDS disorders are few and far between. This complicates an assessment of the TDS hypothesis, not least because only a limited range of chemicals have been investigated. Studies of paternal and maternal pesticide exposures in agricultural occupational settings have reported associations with cryptorchidisms and hypospadias; however, due to their design, they could not pinpoint specific chemicals (Pierik et al. 2004, Carbone et al. 2006). There is evidence for associations of diethylstilboestrol (DES) (Palmer et al. 2009) and polybrominated diphenyl ethers (Carmichael et al. 2010) with the risk of developing cryptorchidisms. Associations between testicular germ cell cancers and exposure to chlordanes, \textit{p},\textit{p}-dichlorodiphenyldichloroethylene (\textit{p},\textit{p}-DDE) and certain 3,3',4,4',5-pentachlorobiphenyls (PCBs) have been detected in several epidemiological studies, but the magnitude of effects was relatively small (Hardell et al. 2003, 2004, 2006, McGlynn et al. 2008). There are several reports of associations between phthalate exposure during pregnancy and changes in AGD (Swan et al. 2005, Bustamante-Montes et al. 2008, Swan 2008, Suzuki et al. 2012), but as yet there is no information whether phthalates are capable of contributing to the risk of developing cryptorchidisms, hypospadias or testis cancer. Other chemicals identified as antiandrogens in animal models or \textit{in vitro} assays, such as certain azole pesticides, benzophenones, parabens or synthetic musks have not been investigated in epidemiological studies. Of the chemicals for which associations with TDS disorders have not been investigated in epidemiological studies. A study of the AR antagonist \textit{p},\textit{p}-DDE (You et al. 1999) dosed pregnant dams with \textit{p},\textit{p}-DDE (10 and 100 mg/kg per day) from gestational day (GD) 14 to 18, during the male programming window. Effects on landmarks of male sexual differentiation (changes in AGD and retained nipples) were only observed at the higher dose of 100 mg/kg per day. The concentrations of \textit{p},\textit{p}-DDE measured in the male foetuses on GD15, 17 and 19 reached values between 2 and 7 \textmu mol/l, a concentration range associated with 20–70% AR antagonism in \textit{in vitro} AR antagonist assays based on MDA-kb2 cells (Wilson et al. 2002, Orton et al. 2011) or CHO-K1 cells (Kojima et al. 2004). The foetal \textit{p},\textit{p}-DDE levels that resulted from the smaller dose of 10 mg/kg per day to the dams (0.2–0.35 \textmu mol/l) were too low to produce \textit{in vitro} AR antagonism and in fact did not elicit AGD changes or retained nipples in the study by You et al. (1999) (Fig. 1).

This interesting concordance led us to assess the magnitude of combined antiandrogenic effects that can be expected on the basis of published measurements of the human tissue levels of antiandrogenic chemicals and their \textit{in vitro} potency. In approaching this issue, we could rely on extensive evidence that the joint effects of multi-component mixtures of \textit{in vitro} AR antagonists (up to 30 components) can be approximated quite well by using the mixture assessment concept of dose addition (Birkhoj et al. 2004, Kjæstad et al. 2010, Ermler et al. 2011, Orton et al. 2012, 2013). According to the principles of dose addition, a concentration of \textit{p},\textit{p}'-DDE associated with \textit{in vitro} activity (and accordingly, a foetal concentration linked with \textit{in vivo} effects) can be replaced with several equi-effective fractions of other active chemicals, without loss of effect. This opened the way for making an attempt of predicting the combined effects of antiandrogens in human tissues entirely by modelling, without conducting the actual mixture experiments.

However, the dose addition principle together with application of an \textit{in vitro} AR antagonist assay meant that we had to restrict our analysis to AR antagonists. The possible contribution of antiandrogens that operate through other modes of action, for example phthalates, could not be taken into account directly, because such agents are without effect in \textit{in vitro} AR antagonist assays. It is therefore not possible to integrate the effects of AR antagonists and those of chemicals that suppress foetal androgen synthesis at the level of AR antagonism. This can only be achieved by conducting \textit{in vivo} studies, but considering that only a handful of chemicals have been evaluated \textit{in vivo}, exclusive reliance on \textit{in vivo} data would have severely limited the scope of our analysis. The exclusion of phthalates from the analysis will have to be reflected on carefully when it comes to assessing the implications of our observations (see ‘Discussion’ section).

To realise the aims of our study, we had to rely on chemicals for which concentration–response
Reproductive toxicity after developmental exposure

Figure 1 Illustration of the tissue dosimetric approach by You et al. (1999). Shown is how the foetal tissue concentrations of p,p’-DDE attained through maternal dosing relate to the in vitro AR antagonistic effects of p,p’-DDE measured by Orton et al. (2011), bottom graph. The two vertical arrows in the bottom graph are the two foetal p,p’-DDE tissue levels measured at gestational day 19. It can be seen that the lower maternal dose which was not associated with demasculinising effects did not give rise to in vitro AR antagonistic effects. In contrast, the higher maternal dose induced marked demasculinising effects and gave rise to foetal p,p’-DDE levels that produced 70% AR antagonistic effects in vitro.

Table 1

<table>
<thead>
<tr>
<th>Maternal dose (mg/kg per day)</th>
<th>Foetal levels at GD19 (µM)</th>
<th>Effects measured in male offspring</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>0.2</td>
<td>No effects</td>
</tr>
<tr>
<td>100</td>
<td>4</td>
<td>Changes in AGD Retained nipples</td>
</tr>
</tbody>
</table>

AR antagonistic effects in vitro at foetal levels

Figure 1

AR antagonistic effects in vitro at foetal levels

Table 1

<table>
<thead>
<tr>
<th>Concentration (µM)</th>
<th>Normalised luminescence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.001</td>
<td>100</td>
</tr>
<tr>
<td>0.1</td>
<td>70</td>
</tr>
<tr>
<td>1</td>
<td>50</td>
</tr>
<tr>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Materials and methods

Chemicals

5α-Dihydrotestosterone (DHT, CAS# 521-18-6, >97% purity) was purchased from Steraloids Ltd, (London, UK) bisphenol-A (BPA, CAS# 80-05-7, >99%), n-butyl paraben (CAS# 94-26-8, >99%), n-propyl paraben (CAS# 94-13-3, >99%), perfluoro-octane sulfonate (tetrabutylammonium salt) (PFOS, CAS# 111873-33-7, >95%), 2,2,4,4'-tetrahydroxybenzophenone (benzophenone 2, BP2, CAS# 131-55-5), 2-hydroxy-4-methoxybenzophenone (benzophenone 3 (BP3), CAS# 131-57-7, 98%), butylated hydroxyanisole (CAS# 25013-16-5, >98.5%), butylated hydroxytoluene (CAS# 128-37-8, >99%), and benzo(α)pyrene (BaP, CAS# 50-32-8) were purchased from Sigma–Aldrich Co (Dorset, UK). Ethyl paraben (CAS# 120-47-8, 99%) and methyl paraben (CAS# 99-76-3, 99%) were obtained from Acros Organics (Loughborough, UK) and PCB 126 (CAS# 57465-28-8), hexahydrohexamethylcyclopentabenzopyran (galaxolide, HHCB, CAS# 1222-05-5) and 6-acetyl-1,1,2,4,4,7-hexamethyldiametadial (tionalide, AHTN, CAS#1506-02-1) from LGC Promochem (Teddington, UK). 3-Benzyldiene camphor (3-BC, CAS# 15087-24-8) was provided by Induchem AG (Volketswil, Switzerland), 2,2',4,4',6-pentabromodiphenyl ether (BDE100, CAS# 189084-64-8) by Cambridge Isotope Laboratories, Inc. (Ibstock, UK), p,p’-dichlorodiphenyldichloroethylene (p,p’-DDE, CAS# 72-55-9) by Greyhound Chromatography (Birkenhead, UK) and 4-methylbenzylidene camphor (4-MBC, CAS# 36861-47-9) by Merck & Co (Hoddeston, UK).

PCB 118 (CAS# 31508-00-6) was obtained from Ultra Scientific (Teddington, UK), 2,2’,3,4,4’,5’-Hexachlorobiphenyl (PCB 138, CAS# 35065-28-2), 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB 153, CAS# 35065-27-1) and 2,2’,3,4,4’,5,5’-heptachlorobiphenyl (PCB 180, CAS# 35065-29-3) were purchased from Riedel-de-Haen (Dorset, UK). Stock solutions were made by dissolving the compounds in ethanol (≥99.7%, VWR International Ltd, Lutterworth, UK). Stock solutions and all dilution series were stored at −20 °C. All other reagents were obtained from Sigma–Aldrich Co. or Invitrogen (Paisley, UK).

Cell culture and (anti-)androgenicity assay

MDA-kb2 cells with the MMTV.Luciferase.neo reporter gene construct (Wilson et al. 2002) were routinely maintained in Leibowitz-15 (L-15) medium (Invitrogen) supplemented with 10% FCS (Invitrogen) at 37 °C without additional CO2. We employed a modified version of the original assay protocol by Wilson as described in Ermler et al. (2010, 2011). The androgen (DHT, 0.25 nmol/l) was used as a positive control and to establish a baseline for co-exposure for testing of AR antagonists.
Table 1 Tissue levels of each compound for an average and a high exposure scenario.

<table>
<thead>
<tr>
<th>Compounds (in order of EC50)</th>
<th>Average levels (M)</th>
<th>High levels (M)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polybrominated diphenyl ether 180</td>
<td>8.12 × 10⁻¹³</td>
<td>1.59 × 10⁻¹¹</td>
<td>Meneses et al. (1999), Covaci et al. (2002) and Ramos et al. (2007)</td>
</tr>
<tr>
<td>Benzophenone 2</td>
<td>7.50 × 10⁻¹⁰</td>
<td>7.00 × 10⁻¹⁰</td>
<td>Konop et al. (2002) and Park et al. (2007)</td>
</tr>
<tr>
<td>Polychlorinated biphenyl 118</td>
<td>7.08 × 10⁻¹⁰</td>
<td>2.83 × 10⁻⁹</td>
<td>Galassi et al. (2008)</td>
</tr>
<tr>
<td>p,p'-DDE</td>
<td>1.90 × 10⁻¹⁰</td>
<td>4.70 × 10⁻⁹</td>
<td>Neal et al. (2008)</td>
</tr>
<tr>
<td>Benzo[a]pyrene</td>
<td>1.98 × 10⁻⁹</td>
<td>5.55 × 10⁻⁸</td>
<td>Schoenfelder et al. (2002) and Vandenberg et al. (2007)</td>
</tr>
<tr>
<td>Bisphenol-A</td>
<td>8.76 × 10⁻⁶</td>
<td>8.28 × 10⁻⁸</td>
<td>Konop et al. (2002)</td>
</tr>
<tr>
<td>Polychlorinated biphenyl 126</td>
<td>1.18 × 10⁻⁹</td>
<td>3.54 × 10⁻⁹</td>
<td>Hutter et al. (2005) and Schiavone et al. (2010)</td>
</tr>
<tr>
<td>Galaxolide (HHCB)</td>
<td>7.10 × 10⁻¹⁰</td>
<td>1.59 × 10⁻⁸</td>
<td>Konop et al. (2002) and Park et al. (2007)</td>
</tr>
<tr>
<td>Butylated hydroxyanisole</td>
<td>3.63 × 10⁻⁹</td>
<td>8.75 × 10⁻⁹</td>
<td>Conacher et al. (1986)</td>
</tr>
<tr>
<td>Butylated hydroxyanisole</td>
<td>5.09 × 10⁻¹⁰</td>
<td>1.02 × 10⁻⁹</td>
<td>Konop et al. (2002) and Park et al. (2007)</td>
</tr>
<tr>
<td>Polybrominated diphenyl ether 100</td>
<td>9.74 × 10⁻¹⁰</td>
<td>1.21 × 10⁻⁸</td>
<td>Konop et al. (2002) and Park et al. (2007)</td>
</tr>
<tr>
<td>Tonalide (AHTN)</td>
<td>1.77 × 10⁻¹⁰</td>
<td>3.10 × 10⁻⁹</td>
<td>Hutter et al. (2005) and Schiavone et al. (2010)</td>
</tr>
<tr>
<td>Benzo[a]pyrene 3</td>
<td>8.09 × 10⁻¹⁰</td>
<td>6.00 × 10⁻⁷b</td>
<td>Hany &amp; Nagel (1995) and Schlumpf et al. (2010)</td>
</tr>
<tr>
<td>Polybrominated diphenyl ether 153</td>
<td>2.13 × 10⁻¹⁰</td>
<td>1.67 × 10⁻⁸</td>
<td>Konop et al. (2002) and Park et al. (2007)</td>
</tr>
<tr>
<td>Perfluorooctane sulfonate</td>
<td>2.70 × 10⁻⁸</td>
<td>1.56 × 10⁻⁷</td>
<td>Kannan et al. (2004), Midas et al. (2006), Fromme et al. (2007) and Karrman et al. (2007, 2008)</td>
</tr>
<tr>
<td>3-Benzylidene camphor</td>
<td>4.81 × 10⁻¹⁰a</td>
<td>8.32 × 10⁻⁸a</td>
<td>Janjua et al. (2004) and Schlumpf et al. (2010)</td>
</tr>
<tr>
<td>4-Methylbenzylidene camphor</td>
<td>4.54 × 10⁻¹⁰</td>
<td>7.86 × 10⁻⁸</td>
<td>Conacher et al. (1986)</td>
</tr>
<tr>
<td>n-Butyl paraben</td>
<td>2.46 × 10⁻¹¹</td>
<td>1.09 × 10⁻¹⁰</td>
<td>Darbre et al. (2004)</td>
</tr>
<tr>
<td>n-Propyl paraben</td>
<td>2.34 × 10⁻¹¹</td>
<td>2.34 × 10⁻¹¹</td>
<td>Darbre et al. (2004)</td>
</tr>
<tr>
<td>Ethyl paraben</td>
<td>2.21 × 10⁻¹¹</td>
<td>8.17 × 10⁻¹¹</td>
<td>Darbre et al. (2004)</td>
</tr>
<tr>
<td>Methyl paraben</td>
<td>1.54 × 10⁻¹⁰</td>
<td>3.53 × 10⁻¹⁰</td>
<td>Darbre et al. (2004)</td>
</tr>
</tbody>
</table>

*Adjusted values to avoid domination of the mixture effect. *No direct tissue levels available, thus the values were estimated from intake levels, compared with related compounds (BP2 with BP3 and 4-MBC with 3-BC).

Statistical concentration–response analysis

Statistical dose response regression analyses were conducted according to the best-fit approach (Scholze et al. 2001), by independently fitting various non-linear regression models to the same data set and selecting the best-fitting model on the basis of a statistical goodness-of-fit criterion, as described earlier (Ermiler et al. 2010, 2011).

Calculation of mixture effect predictions

Predictions for the combined effects of the test compounds were made by using concentration addition (CA), generally under the assumption of ‘non-interaction’ (i.e. each chemical in the mixture contributes to a combined effect, but without exacerbating or diminishing the effects of the other components). The mathematical and statistical procedures used for calculating mixture effects according to CA were the same as those described in Ermiler et al. (2011) and Orton et al. (2012). The calculation of any effect concentration of a mixture under the hypothesis of CA was carried out using equation 1.

\[
EC_x (\text{mixture}) = \left( \frac{1}{n} \sum_{i=1}^{n} \frac{p_i}{EC_{xi}} \right)^{-1}
\]

where \( EC_{xi} \) is the effect concentration of the \( i \)th compound in the mixture that on its own produces the same quantitative effect \( x \) as the mixture and \( p_i \) the relative proportion of the corresponding individual concentration present in the total mixture concentration. The individual effect concentrations were derived from the concentration–response functions for the compounds (Fig. 2 and Supplementary Table 1, see section on supplementary data given at the end of this article) by using their inverse functional form. The values for \( p_i \) were developed from human tissue levels (Supplementary Table 2).

Owing to its mathematical features, the CA concept cannot be used to calculate the effect concentrations associated with mixture effects that exceed the maximal AR antagonistic effect of the least efficacious compound present in the mixture. In the case investigated here, this limitation was introduced by BaP which showed AR antagonistic effects of a magnitude not exceeding 70% of the effect seen with DHT, corresponding to an AR antagonistic effect of 30%. To construct CA prediction curves that covered the entire range of antagonistic effects, we assumed that BaP did not contribute to the overall mixture effect at effect concentrations beyond the 30% effect.

Collection of tissue level data for AR antagonists and conversion to serum levels as molar concentrations

Data of human tissue levels of AR antagonistic chemicals were collected and converted to molar concentrations (Table 1, with an emphasis on European data. To construct average exposure scenarios, we used averaged values, but for the assessment of high exposure scenarios we employed the highest reported values. For the u.v.-filters benzophenone 2 and 4-methylbenzylidene camphor, tissue level data were not available. To bridge this gap, we assumed that adipose tissue levels were similar to those of the related compounds benzophenone 3 and 3-BC. We converted human serum levels (ng/ml) to molar concentrations, but where only adipose tissue levels were available. To bridge this gap, we assumed that tissue levels were similar to those of the related compounds benzophenone 3 and 3-BC.
serum concentrations. Conversions of data from serum levels on a lipid basis (ng/g) to concentrations on a wet basis (ng/ml) were performed by dividing the levels by a factor of 129.8. Reported adipose tissue levels were further divided by a factor of 4.2 to obtain an estimate of the concentration on a lipid basis. These conversion factors were specifically validated for \( p,p' \)-DDE (López-Cervantes et al. 2004), but in the absence of similar validated conversion factors for the compounds considered here, we applied these factors generally to all the 22 selected chemicals.

Results

For the 22 chemicals listed in Table 1, we recorded concentration–response relationships for AR antagonism in the MDA-kb2 gene reporter assay (Fig. 2). We utilised the regression models for these chemicals (Supplementary Table 1) to predict their combined additive effects (dose addition) in the MDA-kb2 assay, for two scenarios.

For the first scenario, we modelled average exposures. Accordingly, Fig. 3A shows the anticipated combination effects for a mixture ratio in proportion to average human serum levels of all 22 AR antagonists and in proportion to high-end serum levels (B). The combination effects were calculated by using dose addition (dark grey line) with confidence belts (broken lines). The light grey belts depict predictions derived from extrapolations beyond the single effects of benzo(\( \alpha \))pyrene (for details see ‘Materials and methods’ section).

AR antagonistic effects would therefore not become apparent in the MDA-kb2 assay, in which the 22 selected chemicals were tested at the average molar concentrations in human serum.

In the second scenario, we evaluated the expected joint effects for serum levels equivalent to high exposures. This time, the sum of serum concentrations of all compounds (1.1 \( \mu \)mol/l) was only by a factor of 2.6 lower than the total mixture concentration predicted to produce 10% AR antagonistic effects (ca. 3 \( \mu \)mol/l; Fig. 3B). With the statistical power afforded by the MDA-kb2 assay, which is sufficient to demonstrate the effect magnitudes of 10% (Ermler et al. 2010), this concentration would still be too low to produce measurable effects.

Previous mixture studies from our laboratory were intended to assess the predictability of combination effects (Ermler et al. 2011, Orton et al. 2012, 2013),
and to achieve this, all chemicals had to be combined at mixture ratios proportional to their potency. In this so-called balanced mixture design, the components contribute in equal measure to the joint effect, because the toxic unit or risk unit in equation 1, i.e. the ratio of $p_i$ (the relative proportion of the individual concentration of a component to the total mixture concentration) and $EC_{x_i}$ (the effect concentration of the $i$th compound in the mixture that on its own produces the same quantitative effect $x$ as the mixture) have the same values for all mixture components.

However, in the two scenarios investigated here, this condition was not fulfilled, because the components were assumed to be present in proportion to their concentrations in body fluids. These concentrations are not correlated to the potency of the mixture components. It is therefore to be expected that some chemicals, due to their prevalence and potency, contribute disproportionately to the overall mixture effect, while the impact of others may be negligible. To visualise this for the two scenarios assessed here, we calculated the risk units for each component based on the concentrations present in a mixture expected to produce a 10% AR antagonistic effect (Supplementary Table 2). We then produced rank orders by arranging the risk units according to their magnitude and generated cumulative plots of the sums of risk units (Fig. 4).

For both the average and high exposure scenario, these plots showed that a relatively small number of mixture components explained the majority of the predicted combined effect. In the case of the average exposure scenario (Fig. 4A), the sum of the four largest risk units (0.016, from BPA, BaP, PFOS and benzophenone 2) already amounted to about 80% of the total sum of risk units (0.021). These four chemicals, together with those with the next four largest risk units (PCBs 138, 126, 118 and HHCB), explained 95% of the overall combined effect. Very similar results became apparent for the high exposure scenario (Fig. 4B), only that the rank order of the risk units changed. For high serum concentrations, benzophenone 2 and 3, BPA, PFOS, HHCB, BaP, 3-BC and 4-MBC together made up 95% of the total sum of risk units, while the PCBs and $p,p'$-DDE contributed very little to the combined effect in this scenario. These proportions are close to Pareto's rule, which states that ~20% of the causal factors determine 80% of the effects.

**Discussion**

**Interpretation of findings**

Our calculations show that AR antagonistic combination effects demonstrable in the MDA-kb2 assay are not expected to occur when the selected 22 in vitro AR antagonists are combined at serum concentrations encountered in European countries, neither at levels representative of average exposures, nor at high exposures. It appears that the potency of the selected chemicals is too low to produce effects at serum levels, resulting from environmental exposures. Another way of interpreting our findings would be to say that we did not consider sufficiently large numbers of environmental antiandrogens to reach concentration ranges associated with effects.

**Constraints and limitations**

This last aspect is a consequence of the constraints imposed by the lack of the data required to conduct modelling studies of the kind presented here. There are several hundred chemicals capable of antagonising the AR in vitro (Kojima et al. 2004, Vinggaard et al. 2008), but data about human tissue levels are available only for a small fraction of these substances. As pointed out earlier, this limitation is particularly relevant to the numerous pesticides identified as in vitro AR antagonists (Kojima et al. 2004, Vinggaard et al. 2008, Orton et al. 2011). For these reasons, we were unable to take account of a larger number of chemicals including pesticides.
A second limitation concerns the antiandrogenic modalities that could be incorporated into our study. Certain phthalates may contribute to androgen insufficiency in foetal life, not by blocking the AR as the agents investigated here, but by suppressing foetal androgen synthesis (Howdeshell et al. 2008). However, this mode of action cannot be captured in the MDA-kb2 assay and co-exposure to phthalates would have little impact on the endpoint measured in that assay. For this reason, we could not include phthalates in our calculations. Modelling of the joint effects of AR antagonists and phthalates would have required an integration of combined effects at a higher physiological level, measurable only in in vivo studies where it has been shown that certain phthalates and AR antagonists can work together to affect landmarks of male sexual differentiation in the rat (Christiansen et al. 2009, 2012). However, it is possible to take account of the impact of phthalates in a qualitative manner (see below).

**Defining conditions when combination effects are likely to occur**

Despite these constraints and limitations, our efforts help to define conditions when combination effects of a sufficient magnitude might occur, by applying the principles of dose addition. We found that the sum of the average serum concentrations of our selected AR antagonists was lower by a factor of 48 than the total mixture concentration anticipated to produce a 10% AR antagonistic effect. To achieve an effect of such magnitude, there are two options, both in line with the principles of dose addition: one possibility is to increase the concentration of each of the 22 mixture components 48-fold (which is the option represented in Fig. 3A). Alternatively, if the concentrations of the chemicals are to be kept at the levels determined in serum, the only route open to reach the same effect is by increasing the number of AR antagonistic substances included in the mixture by a factor of 48. This would bring the number of mixture components to 1056 (=22×48). At present, this many AR antagonists are not known, and we have doubts whether such numbers will be identified in human tissues.

However, with the high exposure scenario, we found that the sum of the serum concentrations was only 2.6-fold lower than the mixture concentration needed to provoke effects. If we apply the same calculation to this case, 57 (=22×2.6) AR antagonists at levels equivalent to high-end serum concentrations will have to be combined to achieve a 10% AR antagonistic mixture effect. This number is closer to the number of chemicals with known in vitro AR antagonist properties. Based on these calculations, it can be expected that problematic situations are more likely to arise from high exposures, but not from average exposure scenarios.

**The impact of the magnitude of the AR antagonistic effect**

We have based our predictions on a 10% AR antagonistic effect, a magnitude that can be captured with the statistical power afforded by the MDA-kb2 assay (Erlmer et al. 2010). However, we wondered what the impact on the estimated numbers of mixture components would be if stronger antagonistic effects were demanded, for example 50%. As can be seen from Fig. 3, for both average and high exposures, the requirement to achieve a 50% antagonistic effect would increase the total mixture concentration to about 13 μmol/l, 256 or 11 times higher than the measured serum levels respectively. With the demand of keeping the concentrations the same as those of the 22 chemicals in each scenario, the required number of mixture components will then increase to 5632 (=22×256) in the case of average exposures, and 242 (=22×11) for high exposures, five or four times higher than the numbers necessary to achieve a 10% antagonistic effect. The impact of the required effect magnitude is largely driven by the gradient of the concentration response curve of the mixture, with steeper gradients lessening the impact of effect size.

**The implications of Pareto’s rule**

The cumulative risk unit summations depicted in Fig. 4 show that four (average exposures) or three (high exposures) of the 22 chemicals in the mixtures accounted for 80% of the sum of risk units. This is equivalent to 19% (average exposures) or 14% (high exposures) of the chemicals in the mixtures, close to Pareto’s 20:80 rule. In both cases, more than half of the mixture components contributed minimally to the sum of risk units. These chemicals therefore represent ‘ballast’ that bulks out the estimated numbers of chemicals needed to provoke a combined effect. Although present in the mixtures, their influence is minimal, mainly because their potency is too low to make an impact at the measured serum levels. We note that some chemicals that constitute this ‘ballast’, especially the PCBs and p,p’-DDE, have been the focus of epidemiological studies exploring associations with TDS disorders. Strikingly, none of the AR antagonists contributing most to the mixture effect have been investigated epidemiologically. Application of Pareto’s rule allows us to correct the above estimated numbers of chemicals downwards, to 211 (20% of 1056) and 11 (20% of 57) in the case of average and high-end exposures, respectively, needed to provoke a 10% antagonistic effect in the MDA-kb2 assay. In the case of an effect magnitude of 50%, these numbers reduce to 1126 (20% of 5632) or 48 (20% of 242) for average or high exposures respectively.
Simplifying assumptions and their impact on our estimates

We had to base our calculations on a number of largely unproven assumptions which will be discussed here, in terms of their impact on our estimated antiandrogenic numbers (for a summary see Table 2). Many of the chemicals considered here undergo conjugation reactions, yielding conjugates considered to have no biological activity. These reactions are particularly relevant to phenolic substances, such as BPA, parabens and similar chemicals. The literature we drew on to obtain information about human tissue levels of our chosen chemicals reported total serum or lipid levels, without distinguishing free parent compounds from their conjugates. For this reason, we could not take the impact of conjugation reactions into consideration but qualitatively, this is to be expected to reduce the combined effects of the mixtures and conversely, to increase the numbers of chemicals required to provoke AR antagonistic effects. Owing to a lack of appropriate data, we are at present unable to quantitate this impact. Similarly, it is difficult to factor in the influence of exposure duration on the strength on AR antagonistic effects. While exposures in the in vitro assay only last for 24 h, sensitive foetal tissues come into contact with the chemicals of interest for much longer periods of time.

As mentioned earlier, the impossibility of taking account of antiandrogens that exert their effects via modes of action different from AR antagonism may have led to underestimations of the number of chemicals needed to reach critical foetal levels. Without being able to quantify the impact of, for example phthalates, which lead to androgen insufficiency by suppressing androgen synthesis, their influence can at least be considered qualitatively: their presence will lead to a reduction in the critical number of AR antagonists.

An absence of data also forced us to make simplifying assumptions when constructing the high exposure scenario. The simple combination of high tissue levels, as done for our calculations, presupposes that high tissue levels of contaminants are correlated, i.e. that there are subjects who experience high exposures to all the 22 chemicals considered here. We acknowledge that this is a highly unlikely scenario, representative of a worst-case assumption. However, multiple pollutants are rarely measured in one and the same human tissue specimen, and we could not locate literature where the levels of all of our chosen chemicals were reported together, but such data would be needed to put the reconstruction of a high-end exposure scenario on a more solid footing. We suggest that this issue can be approached by conducting probabilistic analyses beyond the scope of this study. Nevertheless, it is clear that our simplifying assumptions regarding high exposures have driven upwards the anticipated mixture effects, and downwards the estimated number of chemicals.

Implications for extrapolations to physiological scenarios relevant to humans

For the majority of the in vitro AR antagonists considered here, data about the ability to produce antiandrogenic effects in vivo is lacking entirely. For this reason, reflections about the physiological relevance of our analysis have to be undertaken with great care, and by making explicit all relevant assumptions. This exercise will expose factors that are currently undefined, but may have a great impact on the extent of antiandrogenic effects (see the compilation in Table 2).

First, let us apply the scenario investigated thus far to the tissue dosimetric approach taken by You et al. (1999) in their analysis of the antiandrogenic effects of p,p'-DDE in the rat. By using the in vitro AR antagonistic data for p,p'-DDE reported by Wilson et al. (2002) and Kojima et al. (2004), it can be shown that antiandrogenic effects only became manifest when sufficiently high levels of p,p'-DDE had accumulated in the male foetus, levels clearly associated with in vitro AR antagonistic effects. In every likelihood, the dose addition principle also applies here: it should be possible to replace the biologically active internal foetal dose of p,p'-DDE with equi-effective

<table>
<thead>
<tr>
<th>Assumption</th>
<th>Impact on estimated numbers of AR antagonists required to reach critical effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Critical effect magnitude of AR antagonistic effects larger than 10%</td>
<td>Will increase</td>
</tr>
<tr>
<td>Conjugation reactions remove biologically active AR antagonists</td>
<td>Will increase</td>
</tr>
<tr>
<td>Exposure duration of foetal tissues is longer than in the AR antagonist assay</td>
<td>Longer exposure times may increase the effectiveness of AR antagonists, and decrease the number of chemicals needed to reach critical effects</td>
</tr>
<tr>
<td>Only AR antagonists could be considered</td>
<td>Consideration of other antiandrogen modalities will decrease the critical number of chemicals</td>
</tr>
<tr>
<td>High internal exposures are correlated</td>
<td>If high exposures to chemicals are not correlated, larger numbers of AR antagonists will be required to reach critical effects</td>
</tr>
<tr>
<td>Serum levels of AR antagonists are similar to those in foetal tissues</td>
<td>Numbers will increase if foetal levels are lower</td>
</tr>
<tr>
<td>Sensitivity of human foetal tissues is comparable to that of the rat</td>
<td>If the human is more sensitive, estimates of numbers of chemicals to reach critical effects will decrease</td>
</tr>
<tr>
<td>Mutations and similar factors predispose subgroups of the population to greater sensitivity to AR antagonists</td>
<td>Critical number of AR antagonists will decrease</td>
</tr>
</tbody>
</table>

Table 2 Assumptions that are currently difficult to verify but which have an impact on the estimated number of AR antagonists necessary to yield critical effects.
fractions of several other AR antagonists, without loss of effect. Whether this is achievable in the rat (let alone the human) with the chemicals investigated here is largely unexplored, but should depend primarily on toxicokinetic factors. It is quite conceivable that the doses of certain in vitro active compounds that have to be administered singly to pregnant dams to attain foetal AR antagonistic tissue levels are so high that maternal toxicity is induced, in which case the in vitro activity of such chemicals will be irrelevant because it cannot be expressed in vivo. Nevertheless, in the light of the available evidence of the behaviour of in vitro AR antagonists in combination (Birkhoj et al. 2004, Kjaerstad et al. 2010, Ermler et al. 2011, Orton et al. 2012, 2013), there is no reason to believe that the 22 chemicals investigated here should not cause antiandrogenicity in the rat if they were present in the foetus at the concentrations shown to produce AR antagonistic effects in vitro in the MDA-kb2 assay. Viewed from the perspective of tissue dosimetry, in vitro–in vivo extrapolations lose much of the mystique that is often attached to them.

If we continue our thought experiment by considering the rat, the next question to be examined concerns the relationship between serum levels of AR antagonists and those in foetal tissues. Again, these relationships are largely unexplored, but it would be plausible to assume that the two concentrations are not drastically different, unless there are processes that lead to the accumulation in foetal tissues of certain chemicals. The blood–placenta barrier is another factor to consider, but many chemicals evaluated here are able to cross this barrier.

It remains to reflect on the critical AR antagonistic effect magnitude that a foetus is unable to tolerate without suffering androgen insufficiency. It is presently unknown whether this is equivalent to a 10% effect or closer to 50%, and will not be known in the foreseeable future. However, as discussed above, the likely impact depends on the gradient of the underlying dose–response curves.

Finally, we need to deliberate on the question of the sensitivity of the human foetus relative to that of the rat foetus. These sensitivity differences are currently unknown, but certain assumptions can be made and their impact can be elaborated. The sensitivity of the foetus is the factor likely to have the largest impact on the number of antiandrogens that need to be invoked to make a case for potentially adverse tissue concentrations. If the sensitivity of foetal tissues is by a factor of only 10 higher than the sensitivity of an in vitro assay with MDA-kb2 cells, the predicted dose additive curves in Fig. 3 will shift by one order of magnitude towards lower concentrations. In the case of the high exposure scenario investigated here, this would mean that the 22 in vitro AR antagonists together would already show joint effects if they were present at these levels in the foetus. Whether this is realistic is at present difficult to judge, but an answer to this question will depend on better information about the relative sensitivities of rat and human foetuses to AR antagonists. Similar considerations apply to subgroups of the population with enhanced sensitivity to AR antagonists.

Is there an explanation gap?

Our analysis forces the conclusion that rampant TDS disorders cannot at present be explained in terms of average human exposures to 22 AR antagonists known to be present in human tissues. Their potencies and their tissue levels are too low to attain AR antagonistic effects of a critical magnitude. Conversely, the number of AR antagonists that one would need to invoke, under the assumption that both their tissue levels and their potencies are comparable to those of known AR antagonists present in human tissues, reaches 250–5500 chemicals. The upper estimate even exceeds the 2000 in vitro AR antagonists estimated on the basis of quantitative structure–activity relationships to be in commercial use (Vinggaard et al. 2008).

The picture that emerges in the case of high exposures is not as clear-cut. Here, between 10 and ~250 chemicals with potencies and tissue levels comparable to known AR antagonists would be required to attain critical effects, and clearly these numbers seem to be more realistic in relation to the number of known AR antagonists. But even under this scenario, there is currently an explanation gap because the lower estimate of about ten chemicals applies to agents that make a large contribution to a joint effect, according to the Pareto principle. The identity of such chemicals is currently not fully known.

It would appear that these explanation gaps can only be bridged by conjuring up as yet undiscovered high-potency AR antagonists, or alternatively high exposures to unknown agents of average potency. Furthermore, it is clear that it will be difficult to explain TDS disorders solely on the basis of AR antagonists. Other antiandroge

With the realisation of the possible human health consequences of suppressing prostaglandin synthesis in foetal life, an additional ‘antiandrogenic’ modality has recently become the focus of attention. Four epidemiological studies have shown that the use of paracetamol (acetaminophen) and other analgesics in pregnancy is associated with an increased risk of cryptorchidism in boys (Berkowitz & Lapinski 1996, Jensen et al. 2010, Kristensen et al. 2011a, Snijder et al. 2012), and exposure to these drugs is surprisingly high. Paracetamol (acetaminophen) and aspirin were shown to induce antiandrogenic effects by a mechanism involving suppression of prostaglandins, agents important for
male sexual differentiation (Kristensen et al. 2011a). A variety of other endocrine disrupting chemicals have been identified as being capable of suppressing prostaglandin synthesis in vitro (Kristensen et al. 2011b). It remains to be seen whether consideration of this new antiandrogenic modality might help to bridge the explanation gaps that we exposed here, but we note that in vitro potencies of many prostaglandin-suppressing endocrine disrupters are higher than those reported for AR antagonists.

It will be necessary to search for, and identify, new antiandrogenic chemicals that are present in human tissues in an ‘exposome’ approach. This requires systematic and concerted efforts, an area of research that has been neglected in the past, very much to the detriment of environmental epidemiology. Stephen Rappaport’s lament (Rappaport et al. 2012) of the state of environmental epidemiology also applies to antiandrogens and the search for explanations of TDS disorders: ‘... with few exceptions, the identities of major environmental toxicants and their roles in causing chronic disease have not been addressed. Given the poor state of knowledge about health-imparing environmental exposures, epidemiologists pursue narrow hypotheses that largely skirt disease aetiology in favour of known environmental risk factors even when the attributable risks are small. Although such hypothesis-driven studies confirm some environmental sources of disease, they offer only fragments of our understanding of the major causes and mechanisms of chronic diseases.’

Discussion from meeting

Philippe Grandjean (Odense, Denmark): Your provocative presentation is very interesting and your conclusions might be valid, but would be more convincing if you built in a degree of susceptibility. Thus, vulnerability should also be included in your Monte Carlo model. You modelled the sensitivity to androgen receptor antagonists as being tenfold higher in utero than suggested by in vitro assays, but there are possibly also a variety of factors, particularly on an as yet unknown genetic predisposition, which must be present to explain the gap. This is a variable which you must consider to determine if genetic predisposition rather than the number of chemicals determines the outcome.

A Kortenkamp (Uxbridge, UK): That is a good suggestion. Rather than modelling, we are trying to define a framework which will isolate factors that will make a big difference from those which do not have such a strong impact. The sensitivity, vulnerability and predisposition of the subjects will have a massive impact on the number of chemicals we have to invoke. In this context, the magnitude of the effect is not as important.

Louis Guillette (Charleston, USA): It has been emphasised at this meeting that mixtures are important. Studies in humans, wildlife and laboratory animals show that multiple endocrine activities are taking place simultaneously. Earl Gray has examined multiple modalities with antiandrogenic activity and has described ‘something from nothing’ effects due to the summation of minor events. You should consider what modalities other than antiandrogenic substances could have oestrogenic activity. Glucocorticoid signalling might also be involved. Michael Eisenberg (this volume) described many isoforms of the androgen receptor (AR). Most laboratory tests are targeted on single clones, but there is a marked diversity in the AR in the human population especially between different ethnic populations.

A Kortenkamp: We have conducted various AR in vitro antagonist assays and find that the potency is very comparable with agreement between different assays. Modalities other than AR antagonism are difficult to model because it is not clear how these different modalities result in common mixture effects at a level of biological organisation further removed from interaction with receptors. We have taken account of this by qualifying our estimates with strong provisos. There is currently no other way of dealing with this.

Shanna Swan (New York, USA): There are many non-chemical endocrine disrupters such as stress, nutrition, sleep and lack of exercise. We have seen that in low stress mothers there is a twofold increased susceptibility to phthalates in relation to the anogenital distance (AGD) of the offspring. Some of these multiple non-chemical factors can act as antiandrogens.

A Kortenkamp: Your point is much appreciated. These non-chemical factors probably act by altering sensitivity to chemical compounds and can be taken into account in our framework by making different assumptions about the vulnerability of the foetus.

Anne Marie Vinggaard (Søborg, Denmark): Your estimations of the hazard index might not be valid because these are based only on AR antagonism. You have not included chemicals which inhibit testosterone production and these have an additive effect to AR antagonism. Also, the IC₅₀ or IC₁₀ values might not be appropriate for your calculations because they fail to take account of protein binding when extrapolating from in vitro to the in vivo situation. For example, the effect of PAHs has been shown to be more potent in vivo if protein binding in vitro is considered.

A Kortenkamp: I agree that other modalities are relevant to the disorders that we see, but it is difficult to take these into account with our tentative modelling approach other than by stating the direction in which the presence of phthalates and other chemicals with different modes of action will affect our estimates. They will likely reduce the number of chemicals we need to invoke. That is currently the only way to take account of the factors you mentioned because it is impossible to aggregate the effects of phthalates and AR antagonists at the tissue level, where we measure the concentrations
in tissue and at the cellular level. Animal models are required to explore the combined effect.

**Greet Schoeters** (Mol, Belgium): You complicate matters by studying mixtures rather than single compounds, but the outcome of your in vitro assay addresses a single target. Endocrine disruptors cause syndromes such as testicular dysgenesis syndrome (TDS), which are a mixture of different events. How does this fit into your model?

**A Kortenkamp**: We were investigating the magnitude of the problem by considering mixture effects. It will be near impossible to explain current trends in male reproductive health without taking account of mixtures. In order to make progress, we had to simplify matters somewhat by making sometimes quite crude assumptions.

**Jerry Heindel** (NIEHS, USA): How many mixtures have you tested and are you sure you are correct? If you predict that a mixture will have no effect, have you tested the mixture to make sure?

**A Kortenkamp**: We have performed the experiments and found that mixtures had no effect as calculated.

### Supplementary data

This is linked to the online version of the paper at [http://dx.doi.org/10.1530/REP-13-0440](http://dx.doi.org/10.1530/REP-13-0440).

### Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

### Funding

Funding from the European Commission, FP7 programme (CONTAMED, grant number 212502) and the United Kingdom Food Standards Agency (contract number T01045) is gratefully acknowledged. Funding sources had no involvement in the study design, data collection, analysis, interpretation or publication. This article is based on work presented at the 7th Copenhagen Workshop on Endocrine Disrupters, which was supported by the Danish Ministry of the Environment – Environmental Protection Agency. Publication of this special issue was supported by the Society for Reproduction and Fertility. The authors do not have any relationships to the Society for Reproduction and Fertility. A Kortenkamp is a partner in a Danish Env Protection Agency. At the time of the COW workshop, A Kortenkamp did not have any relation with the Danish EPA, nor has the grant any direct relation to the work we describe in the contribution to Reproduction. All other authors declare no relationship with the Danish EPA.

### References


Orton F, Rosivatz E, Scholze M & Kortenkamp A 2012 Competitive androgen receptor antagonist as a factor determining the predictability of cumulative antiangenic effects of widely used pesticides. Environmental Health Perspectives 120 1578–1584. (doi:10.1289/ehp.1205391).


Received 10 September 2013
First decision 24 September 2013
Revised manuscript received 20 December 2013
Accepted 16 January 2014